Bud Selig

MLB sues Biogeneis, Anthony Bosch, claims interference with contract

57 Comments

Major League Baseball has filed its lawsuit against Anthony Bosch and Biogenesis. There are multiple other defendants as well.* The claim: that by selling drugs to major league players, Biogenesis and Anthony Bosch “enabled such Players to possess and/or use [performance enhancing drugs] and thus knowingly and intentionally caused and/or induced such Players to breach their contractual obligations under MLB’s Joint Drug Prevention and Treatment Program not to possess or use [performance enhancing drugs].”

UPDATE: The entire complaint can be seen below.

This morning my primary legal criticism of the claims were that Major League Baseball could not show damages as a result of these acts. I have not changed my mind, if for no other reason than the contract MLB claims interference with is the Joint Drug Agreement, in which MLB has no direct financial interest. Indeed, it EXPECTS the JDA to be breached and has built in a punishment system because of it. When a player takes PEDs he violates it, by definition. Major League Baseball does not have a cause of action for breach of contract against them. How Major League Baseball expects to get greater satisfaction from an alleged third party tortfeasor than it could get from a party to the contract is … interesting.

That said, here are their damages allegations:

Due to Defendants’ actions, MLB has suffered damages, including the costs of investigation, loss of goodwill, loss of revenue and profits and injury to its reputation, image, strategic advantage and fan relationships.

Nothing surprising. But also nothing which seems at all to be the stuff of a meritorious lawsuit.  It’s loss of goodwill, outside of that involving a few columnists, is impossible to quantify. Its revenue and profits are at record highs and many would argue that these were achieved thanks in part to the PED-inflated offensive numbers of the past 20 years, not despite it.

This lawsuit is crazy on its face. It should be thrown out of court. I am shocked Major League Baseball found someone who would file it.

source:

source:

source:

source:

source:

source:

source:

source:

source:

source:

source:

source:

source:


source:

*The defendants:  BioGenesis of America, LLC, a Florida Limited Liability Company (“BioGenesis”); Biokem, LLC, a Florida Limited Liability Company (“Biokem”); Anthony P. Bosch (“Bosch”); Carlos Acevedo (“Acevedo”); Ricardo J. Martinez (“Martinez”); Juan Carlos Nunez (“Nunez”); Marcelo Albir (“Albir”); and Paulo da Silveira

Giants acquire Eduardo Nunez from the Twins

ARLINGTON, TX - JULY 07: Eduardo Nunez #9 of the Minnesota Twins throws for an out at first in the fourth inning during a game against the Texas Rangers at Globe Life Park in Arlington on July 7, 2016 in Arlington, Texas.  (Photo by Sarah Crabill/Getty Images)
Sarah Crabill/Getty Images
5 Comments

The Giants have acquired All-Star infielder Eduardo Nunez from the Twins in exchange for minor league pitcher Adalberto Mejia, the club announced on Thursday night.

Nunez, 29, went 0-for-4 in Thursday night’s game against the Orioles. He’s hitting .296/.325/.439 with 12 home runs, 47 RBI, 49 runs scored, and a league-best 26 stolen bases in 391 plate appearances this season. Nunez has played mostly at shortstop this season, but has also logged significant time at third base and a handful of games at second base, so he’ll give the Giants some versatility.

Nunez will likely play a lot of third base for the Giants as Matt Duffy is still sidelined with a strained left Achilles. He’s earning $1.475 million this season and will enter his third and final year of arbitration eligibility heading into 2017.

Mejia, 23, was considered the Giants’ seventh-best prospect by MLB Pipeline. He earned a promotion to Triple-A Sacramento last month after posting a 1.94 ERA with Double-A Richmond. In seven starts with Sacramento, he has a 4.20 ERA with a 43/11 K/BB ratio in 40 2/3 innings.

With a roster spot open, the Twins called up infield prospect Jorge Polanco from Triple-A Rochester, per MLB.com’s Rhett Bollinger.

Report: Mariners’ Taijuan Walker drawing “strong” trade interest

SEATTLE, WA - JUNE 08:  Starting pitcher Taijuan Walker #44 of the Seattle Mariners looks on from the dugout after completing eight innings against the Cleveland Indians at Safeco Field on June 8, 2016 in Seattle, Washington.  (Photo by Otto Greule Jr/Getty Images)
Otto Greule Jr/Getty Images
3 Comments

Bob Nightengale of USA TODAY reports that the Mariners have received “strong” trade interest for starter Taijuan Walker. The right-hander is currently on the mend from tendinitis in his right foot.  He’ll throw a bullpen on Friday at Wrigley Field with scouts in attendance.

Walker, 23, has a 3.66 ERA with an 80/18 K/BB ratio in 86 innings this season. It’s his first bit of sustained success at the major league level. What’s arguably just as intriguing is the fact that Walker will be under team control through 2020.

The Mariners have been hovering around .500 for the last month and entered Thursday six games behind the first-place Rangers in the AL West and 4.5 games out of the second AL Wild Card slot, behind three other teams as well as the two Wild Card leaders. It’s enough uncertainty which could push the Mariners to sell.